Test drug radotinib for early Parkinson’s disease
Part of Brain & nervous system clinical trials.
This Phase 2 study tests whether radotinib is safe and tolerable, and whether it can help people with early Parkinson’s disease. It also checks how the body absorbs and processes the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 40 to 80, and you’ve had Parkinson’s symptoms for 3 years or less
- A specialist has diagnosed “clinically probable Parkinson’s disease,” and you have documentation of symptom start time
- Your DaT-scan (a brain imaging test for dopamine nerve loss) was positive, read at the local site
- Your Parkinson’s severity is mild (Hoehn & Yahr stage 2.5 or lower)
- You have not taken Parkinson’s symptom medicines before (and you don’t need to start them within 6 months)
- Your MRI shows no other brain or blood-vessel conditions that could explain symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.